2014-04-01 22:16:29 UTC

Gastroenterology Podcast April 2014: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease

An editorial in the April issue of Gastroenterology compares anti-tumor necrosis factor monotherapy with combination therapy for inflammatory bowel disease. A related article in the same issue also compares increased risk of malignancy with adalimumab combination therapy to monotherapy for Crohn's disease Dr. Kuemmerle speaks with editorial co-author Dr. Corey A. Siegel of Dartmouth-Hitchcock Medical Center; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Bressler B, Siegel CA. Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease. Gastroenterology 2014; April; 146(4): 884-887
Full Text

Related:
Osterman MT, Sandborn WJ, Colombel JF, et al. Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease. Gastroenterology 2014; April; 146(4): 941-949
Abstract

 

 

Duration: 18.27m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on IBD

Unmasking the Origins of IBD

June 14, 2018

Call for studies on biological and environmental factors driving differences between ethnicities and between immigrants versus non-immigrants

U.S. Cities Consider Supervised Injection Sites

May 31, 2018

Safe injection facilities can reduce overdoses, disease transmission, and public drug use

IBD: Exercise May Reduce Risk and Improve Symptoms

May 17, 2018

Data needed to clarify specific activity regimens for individual patients